GTX22356

Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Aug 20;33(24):2660-6

Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer.

Okimoto T, Tsubata Y, Sutani A, Fuchita H, Koba N, Hotta T, Hamaguchi M, Miura K, Hamaguchi S, Ohe M, Kuraki T, Harada Y, Maruyama R, Miyamoto N, Kishimoto K, Isobe T
Anticancer research 2014 Jun;34(6):2755-61

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.

Sun JM, Sung JY, Park SH, Kwon GY, Jeong BC, Seo SI, Jeon SS, Lee HM, Jo J, Choi HY, Lim HY
BMC cancer 2012 May 22;12:187

Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.

Tepeli E, Caner V, Büyükpınarbaşılı N, Çetin GO, Düzcan F, Elmas L, Bağcı G
Molecular biology reports 2012 Jan;39(1):335-41

Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.

Yoon YK, Im SA, Min A, Kim HP, Hur HS, Lee KH, Han SW, Song SH, Youn Oh D, Kim TY, Kim WH, Bang YJ
Cancer letters 2012 Aug 28;321(2):128-36

In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas.

Kang CM, Kim H, Cho Y, Kim YS, Hwang HK, Choi HJ, Lee WJ
Pancreas 2012 Apr;41(3):498-500

Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma.

Seyhan EC, Altın S, Cetinkaya E, Sökücü S, Abali H, Buyukpinarbasili N, Fener N
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2011;17(2):110-7

A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Won YW, Park YH, Ahn MJ, Do IG, Ko YH, Park K
Annals of oncology : official journal of the European Society for Medical Oncology 2011 Feb;22(2):417-23

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.

Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH
Lung cancer (Amsterdam, Netherlands) 2010 Jun;68(3):478-83

Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK
Cancer research and treatment : official journal of Korean Cancer Association 2010 Jun;42(2):101-6

Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.

Kim SJ, Han SW, Oh DY, Yi NJ, Kim YJ, Im SA, Yoon JH, Kang GH, Suh KS, Bang YJ, Jang JJ, Kim TY
Anticancer research 2010 Dec;30(12):5245-50

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH, Heo DS
Annals of oncology : official journal of the European Society for Medical Oncology 2009 Aug;20(8):1414-9

No comments: Submit comment

Supportive validation

Submitted by: GeneTex (provider)
Main image
Experimental details: IHC Image using GTX22356 - Detection of ERCC1 by IHC in Human Tonsil